MDLN
Medline Inc.
Stock
$35.61+0.67 (+1.92%)Close Oct 2, 2026
Income statement
| Line | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $28.4B | $25.5B | $23.2B |
| Cost of revenue | $20.9B | $18.5B | $17.3B |
| Gross profit | $7.5B | $7.0B | $5.9B |
| R&D | $80M | $67M | $60M |
| SG&A | $4.5B | $4.1B | $3.9B |
| Other operating expenses | $702M | $655M | $708M |
| Operating income | $2.2B | $2.1B | $1.3B |
| Non-operating income | −$964M | −$900M | −$986M |
| Pretax income | $1.2B | $1.2B | $264M |
| Taxes | $89M | $83M | $30M |
| Net income | $1.2B | $1.2B | $234M |
| Diluted EPS | −$0.01 | — | — |
| Diluted shares | 810.0M | — | — |
| Revenue growth | +11.5% | +9.8% | — |
| Gross margin | 26.4% | 27.3% | 25.3% |
| Operating margin | 7.8% | 8.4% | 5.4% |
| Net margin | 4.1% | 4.6% | 1.0% |